Head-to-head · verified 2026-08-05
Amble Health vs. Embody: prices, fine print, and the honest verdict
Published pricing is incomplete on at least one side, so this matchup compares what can be verified — disclosure, terms, model — and says plainly where you'll need figures in writing.
- Amble Health
- Tirzepatide, all-in at 10 mg
- $300/mo
- Semaglutide, all-in
- Not offered
- Membership fee
- None
- Commitment
- unknown
- Cancellation
- not published
- Pharmacy
- not named
- First-year total (standing rate)
- $3,600
- Price evidence
- Third-party-reported
- Last verified
- 2026-08-05
- Embody
- Tirzepatide (reported, unverified)
- $99/mo — third-party figure; excluded from rankings
- Tirzepatide, all-in at 10 mg
- Offered — no published price
- Semaglutide, all-in
- Not offered
- Membership fee
- None
- Price evidence
- Third-party-reported
Tirzepatide pricing
Amble Health: $300 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Embody carries only a reported figure — $99/mo from a competing comparison site (May 2026), never captured on a provider page — so it is listed, reviewed, and excluded from ranked comparisons pending verification.
Transparency
Amble Health: Third-party-reported (verified 2026-08-05); dispensing pharmacy not publicly named. Embody: Third-party-reported; dispensing pharmacy not publicly named. In this market, a named pharmacy and a dated, source-verified price are worth real money — they are what let you check the claim instead of trusting it.
Commitment & cancellation
Amble Health: unknown; not published. Embody: terms not published.
Amble Health: $300/mo verified all-in; Embody: $99/mo reported, unverified, unranked; verified floor $215 (NexLife); brand rails $349–$449. Basis: all-in monthly, 10 mg maintenance, capture-dated in the dataset.
Two ladders, side by side
The 2.5-to-10 mg climb is the honest stress test: Amble Health holds $300 on every rung (four-month titration: exactly $1,200). A flat ladder makes dose decisions purely clinical; a scaled one attaches an invoice to every escalation — including the post-plateau bump from 10 to 12.5 mg that many patients eventually face. Full framework: the titration cost guide.
The five normalizations, applied to this pair
1 · All-in, not advertised. Amble Health's ranked figure is $300, with no membership to add; Embody's reported $99 can't be normalized because no source page confirms what it includes. 2 · Maintenance basis. Amble Health is dose-flat, so its entry and 10 mg figures coincide. 3 · Terms separated. Amble Health: standing $300, no prepaid tier — standing rates rank, prepaid effectives are labeled beside them. 4 · Evidence tiered. Amble Health: third-party-reported, read 2026-08-05; Embody: third-party-reported. 5 · Pharmacy weighed. Amble Health names no pharmacy; Embody names no pharmacy — in a pharmacy-variance market, disclosure is a scored asset. Run the same five on any roundup you read and most published “cheapest” lists reorder themselves.
Fine print, itemized
Amble Health: no membership — the medication figure is the billed figure; not published; commitment: unknown. Embody: no membership — the medication figure is the billed figure. The pattern to police on both sides is the same: memberships that outlive the medication order, renewal-relative cancellation deadlines, and prepaid terms whose refund language matters more than their discount in a year of live litigation. Cancel in writing; screenshot everything.
Transparency, audited
Amble Health carries third-party-reported pricing (last read 2026-08-05); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Embody carries third-party-reported pricing; its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Our weighting is unapologetic: in a market of identical molecule names, a dated source-verified price and a named pharmacy are the two claims a buyer can actually check, and they carry 25 of 100 formula points between them — the methodology shows the math, and the pharmacy guide decodes every answer the five questions can return.
Switching between them
Neither program locks the door: a Amble Health-to-Embody move is a new intake, a new prescription at the new pharmacy, and a written cancellation at the old shop — typically a one-to-two-week overlap if you time the last fill. What does not move with you: prepaid months, membership balances, and any dose paperwork, so re-state your current rung clearly at the new intake.
Refills, shipping, and the week-to-week reality
Past the pricing page, the operational facts are what a subscriber lives with: Amble Health: shipping unknown; consultation unknown. Embody: shipping, consult, and refill logistics aren’t published in our capture — ask at intake, in writing. Cold-chain shipments run 3–7 days across the market; the recurring failure modes are refill-timing gaps and pharmacy backlogs, so whichever program wins here, order refills a week early and confirm the pharmacy’s current turnaround at intake.
Who should pick which
Pick Amble Health if you want a price that survives titration. Pick Embody if its published terms happen to fit your state, format, or timing. Neither answer is universal — which is the argument for choosing from data with dates on it rather than from whichever ad loaded first.
What verification would take
For Embody, ranking would require: a provider-page capture confirming the reported $99 figure and exactly what it includes; the dose structure (flat or scaled, with the 10 mg tier stated); the pharmacy's name, 503A/503B status, and state licensure; commitment and cancellation terms verbatim. We publish the checklist because the gap is fixable — providers that clear it get ranked on the same arithmetic as everyone else, and readers who ask these questions get the answers this page can't yet print.
If neither one fits
Two programs never exhaust the market — the nearest substitutes on the verified board are OrderlyMeds at $299 (flat, no membership); SkinnyRx at $299 (flat, no membership); Found at $289 (flat, no membership) — or skip straight to the rankings page, where every standard “cheapest / best / no-commitment” question is answered in one sourced sentence.
The brand benchmark both must beat
Neither program exists in a vacuum: FDA-approved Zepbound sits at $449/month at maintenance (LillyDirect or retail KwikPens, ~$350 on TrumpRx, ~$50 for newly eligible Medicare patients), and Wegovy at a flat $349. The cheaper of these two compounded options saves $1,788/year against the Zepbound benchmark — the number that has to justify accepting a not-FDA-reviewed product, per the full trade analysis. When a compounded quote drifts above ~$350, this benchmark starts winning the argument on its own.
The verdict
With incomplete published pricing on one or both sides, get current figures in writing before enrolling with either. Both records, with dates and sources, live in the pricing database.
Quick answers
Which is cheaper, Amble Health or Embody?
Published pricing is incomplete on at least one side; the honest answer is to request current all-in figures in writing from both.
Can I switch between them?
Yes — patients move between telehealth programs routinely; you'll complete the new program's intake and prescriptions restart there. If you're also switching molecule or from compounded to brand, loop in the prescriber; our switching guide covers the clinical side.
Which is easier to cancel, Amble Health or Embody?
Amble Health: not published Embody: terms not published — get them in writing. Cancel in writing either way; memberships cancel separately.
Is there a brand alternative to both?
Yes — Zepbound at $299–$449 via LillyDirect/retail (about $350 on TrumpRx; ~$50 for newly eligible Medicare patients) and Wegovy at a flat $349: FDA-approved products whose prices now sit close enough to make the comparison real.